<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055128</url>
  </required_header>
  <id_info>
    <org_study_id>CX842A2201</org_study_id>
    <secondary_id>2020-003319-91</secondary_id>
    <nct_id>NCT05055128</nct_id>
  </id_info>
  <brief_title>A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole</brief_title>
  <official_title>A Randomized Double-blind, Double Dummy, Active Comparator-controlled Dose-finding Study in Patients With Erosive Esophagitis Due to Gastro-esophageal Reflux Disease (GERD) Los Angeles Grade C or D, and Patients With at Least Partial Symptom Response But Endoscopically Still Unhealed After 8 Weeks History of Standard Treatment Healing Course With Proton-pump Inhibitor (PPI), to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole, and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cinclus Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cinclus Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in patients with erosive esophagitis due to gastro-esophageal&#xD;
      reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial&#xD;
      symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history&#xD;
      of standard treatment healing course with PPI, designed to support dose selection for Phase 3&#xD;
      and to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or&#xD;
      Lansoprazole, and symptom pattern during subsequent 4 weeks treatment with Lansoprazole.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, active comparator-controlled study with a parallel-group&#xD;
      design including four arms with X842 and one arm with Lansoprazole.&#xD;
&#xD;
      Randomization to one of the treatments with X842 twice daily (BID) 25 mg, 50 mg, 75 mg, 100&#xD;
      mg, or Lansoprazole 30 mg once daily (QD) will be based on a 1:1:1:1:1 scheme.&#xD;
&#xD;
      The duration of each patient's participation in the study, including screening, blind&#xD;
      treatment period, and open-label treatment period will be approximately 60 days. The patients&#xD;
      will be randomized for 4 weeks of double-blind treatment and will be provided with&#xD;
      investigational medicinal product for 35 days.&#xD;
&#xD;
      All patients will have an endoscopic evaluation after 4 weeks of treatment. Following the&#xD;
      endoscopic evaluation, all patients will receive subsequent 4 weeks of open-label treatment&#xD;
      with Lansoprazole. Repeated symptom evaluation to detect symptom patterns will be assessed&#xD;
      during this period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing rate of erosive esophagitis</measure>
    <time_frame>Week 4</time_frame>
    <description>To assess the healing rate of erosive esophagitis due to GERD based on endoscopic assessment. Dose selection for X842 (to identify the dose providing the target effect of 85% healing rate) will be supported through assessment of healing of erosive esophagitis after 4 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events (AEs)</measure>
    <time_frame>From Screening (Day -7 to Day 0) until Week 8</time_frame>
    <description>To assess safety and tolerability of the four dose levels of X842 and Lansoprazole, where Lansoprazole will serve as the active comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of heartburn-free 24-hour days</measure>
    <time_frame>Weeks 1, 2, 4 and 8</time_frame>
    <description>To evaluate the percentage to heartburn-free 24-hour days based on eDiary (Reflux Symptom Questionnaire electronic Diary: RESQ-eDiary). The reflux related symptom pattern will be evaluated during the initial 4 weeks treatment with four dose levels of X842 and with Lansoprazole, and the symptom pattern during the subsequent additional 4 weeks (Weeks 5-8) open-label treatment with Lansoprazole. Modified RESQ-eDiary is a validated self-reported questionnaire electronic symptom diary. mRESQ-eD has 3 domains [i.e. Heartburn (min-max: 0-10), Other GERD signs/symptoms (min-max: 0-15) and Regurgitations/Reflux (min-max: 0-8)]. It is used to assess the severity and frequency of gastroesophageal reflux disease symptoms. For severity a 6-point and for frequency a 5-point Likert response format is used. RESQ-eD contains 8 items where 5 assess severity (0=Did not have - 5=Severe) and 3 assess frequency (0=Never - 4=Very often) of symptoms (min-max: 0-33). Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessment of symptom</measure>
    <time_frame>Week 1-8</time_frame>
    <description>Investigator will assess the severity of patients' heartburn, regurgitation and dysphagia in the 7 days prior to the visit. The assessment will include both the severity grade (for severity, items are coded: none, mild, moderate, severe where none represents no complaints, severe represents incapacitating symptoms) and the frequency (for frequency, a 7-graded Likert scale is used, ranges from none of the time to all of the time) of symptoms. Symptoms are scored as follows: none (no complaints), mild (aware of symptom, but easily tolerated), moderate (discomforting symptom, sufficient to cause interference with normal daily activities and/or sleep), severe (incapacitating symptom, with inability to perform normal daily activities and/or sleep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Quality of Life in Reflux and Dyspepsia (QOLRAD) score</measure>
    <time_frame>Baseline, Weeks 1, 2, 4 and 8</time_frame>
    <description>The reflux related symptom pattern will be evaluated during the initial 4 weeks treatment with four dose levels of X842 and with Lansoprazole, and the symptom pattern during the subsequent additional 4 weeks (Weeks 5-8) open-label treatment with Lansoprazole 30 mg QD. The heartburn version of the QOLRAD is a disease specific instrument and contains 25 questions addressing concerns associated with gastrointestinal symptoms. The questions are rated on a seven-grade (1-7) Likert scale, score of 1 represents low quality of life and as higher the score the better is the patient. If 50% or more of the questions in one dimension are completed, the mean value of the completed items should replace the missing responses. The questions are categorized into 5 domains: emotional distress, sleep disturbance, vitality, food/drink problems and physical/social functioning. The score ranges from 1 to 175, higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>X842 25 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 2 tablets (X842 25mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 25 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X842 50 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 2 tablets (X842 50 mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X842 75 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 2 tablets (X842 50 mg + X842 25 mg) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg√ó2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X842 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 2 tablets (X842 50 mg√ó2) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg√ó2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 2 tablets (X842 dummy√ó2) and 1 capsule (Lansoprazole 30 mg) in the morning, and 2 tablets (X842 dummy√ó2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>X842</intervention_name>
    <description>Patients will receive X842 tablets.</description>
    <arm_group_label>X842 100 mg BID</arm_group_label>
    <arm_group_label>X842 25 mg BID</arm_group_label>
    <arm_group_label>X842 50 mg BID</arm_group_label>
    <arm_group_label>X842 75 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>X842 Dummy</intervention_name>
    <description>Patients will receive matching placebo tablets for X842.</description>
    <arm_group_label>Lansoprazole</arm_group_label>
    <arm_group_label>X842 25 mg BID</arm_group_label>
    <arm_group_label>X842 50 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Patients will receive Lansoprazole capsule.</description>
    <arm_group_label>Lansoprazole</arm_group_label>
    <arm_group_label>X842 100 mg BID</arm_group_label>
    <arm_group_label>X842 25 mg BID</arm_group_label>
    <arm_group_label>X842 50 mg BID</arm_group_label>
    <arm_group_label>X842 75 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole Dummy</intervention_name>
    <description>Patients will receive matching placebo capsules for Lansoprazole.</description>
    <arm_group_label>X842 100 mg BID</arm_group_label>
    <arm_group_label>X842 25 mg BID</arm_group_label>
    <arm_group_label>X842 50 mg BID</arm_group_label>
    <arm_group_label>X842 75 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index (BMI) ‚â• 18 and ‚â§ 40 kg/m^2 at screening.&#xD;
&#xD;
          2. Gastro-esophageal reflux disease with endoscopically confirmed esophagitis:&#xD;
&#xD;
               -  LA grade C or D ‚â§7 days before randomization (with or without historical PPI&#xD;
                  treatment) or&#xD;
&#xD;
               -  LA grade A or B ‚â§7 days before randomization and history of treatment with the&#xD;
                  standard healing course of PPI for minimum of 8 weeks prior to screening and ‚â§7&#xD;
                  days of non-treatment during this period and at least partial symptom response&#xD;
                  during the minimum of 8 weeks of PPI treatment.&#xD;
&#xD;
          3. Willing and able to comply with all aspects of the protocol (including capsule&#xD;
             swallowing, diary completion, etc.).&#xD;
&#xD;
          4. Capable of signing informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of any clinically significant cardiovascular, respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease or&#xD;
             disorder.&#xD;
&#xD;
          2. Patients with so-called &quot;alarm features&quot; in symptomatology, like odynophagia, severe&#xD;
             dysphagia, bleeding, weight loss, anemia, and blood in stool pointing to a possible&#xD;
             malignant disease of the gastrointestinal (GI) tract.&#xD;
&#xD;
          3. Present clinically significant psychiatric diagnosis.&#xD;
&#xD;
          4. History of malignancy of any organ system.&#xD;
&#xD;
          5. Presence of esophageal ulcer, stricture, Barrett¬¥s esophagus or suspected esophagitis&#xD;
             secondary to infection, inflammatory disease, ingestion of erosive chemicals or&#xD;
             history of any surgical or medical condition which might significantly alter the&#xD;
             Gastro-oesophageal reflux disease (GERD) status or the absorption, distribution,&#xD;
             metabolism or excretion of drugs.&#xD;
&#xD;
          6. Known severe atrophic gastritis.&#xD;
&#xD;
          7. Any planned major surgery within the duration of the study.&#xD;
&#xD;
          8. History of a positive result for human immunodeficiency virus (HIV), Hepatitis B&#xD;
             surface antigen (HBsAg), antibody to Hepatitis B core antigen (anti-HBcAg), or&#xD;
             antibody to Hepatitis C virus (anti-HCV) or presence of these findings on screening.&#xD;
&#xD;
          9. History of long QTc syndrome (e.g. QTc ‚â•450 ms for males and ‚â•470 ms for females).&#xD;
&#xD;
         10. Cardiac arrhythmias or any clinically significant abnormalities in the resting 12-lead&#xD;
             ECG at the time of screening, as judged by the Investigator.&#xD;
&#xD;
         11. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity.&#xD;
&#xD;
         12. Current or history of alcohol, drug abuse and/or use of anabolic steroids within 2&#xD;
             years prior to screening.&#xD;
&#xD;
         13. Women who are pregnant or breastfeeding.&#xD;
&#xD;
         14. Patients who have previously participated (completed or withdrawn) in this study&#xD;
             CX842A2201.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Unge, MD</last_name>
    <phone>+46 705 763780</phone>
    <email>peter@cincluspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Omega Research Orlando</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334-3275</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onyx Clinical Research, LLC</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Javara Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>3A Research, LLC</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>coastal Carolina Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NMTH 'Tsar Boris III'</name>
      <address>
        <city>Sofia</city>
        <state>Sofia-Grad</state>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DCC XIV Sofia</name>
      <address>
        <city>Sofia</city>
        <state>Sofia-Grad</state>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Medconsult Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MC Exacta Medical OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5809</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Kaspela&quot;</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diagnostive Consultative Center-1 Sliven</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Hera - Gastroenterology office</name>
      <address>
        <city>Sofia</city>
        <zip>1510</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Biomed 99&quot; Ltd</name>
      <address>
        <city>Vidin</city>
        <zip>3700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Libera Scientia s.r.o.</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ResTrial GastroEndo s.r.o.</name>
      <address>
        <city>Praha 4</city>
        <zip>143 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD&quot;Brothers&quot;</name>
      <address>
        <city>Batumi</city>
        <state>Ajaria</state>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A. Aladashvili clinic LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Israeli-Georgian Medical Research Clinic &quot;Helsicore&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD TSMU and Ingorokva High Medical Technology University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emergency Cardiology Center named by acad. G. Chapidze</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD INNOVA - Gestroenterology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz, Dr.Rethy Pal Tagkorhaz</name>
      <address>
        <city>B√©k√©scsaba</city>
        <state>B√©k√©s</state>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem √Åltal√°nos Orvostudom√°nyi Kar</name>
      <address>
        <city>Szeged</city>
        <state>Csongr√°d</state>
        <zip>H-6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Hospital/Clinexpert Gyongyos Ltd.</name>
      <address>
        <city>Gy√∂ngy√∂s</city>
        <state>Heves</state>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szent Borbala Korhaz</name>
      <address>
        <city>Tatab√°nya</city>
        <state>Kom√°rom-Esztergom</state>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinExpert Kft.</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MH Eg√©szs√©g√ºgyi K√∂zpont - Gasztroenterol√≥giai Oszt√°ly</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>J√°vorszky √ñd√∂n K√≥rh√°z</name>
      <address>
        <city>Vac</city>
        <state>Pest</state>
        <zip>H-2600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Obudai Egeszsegugyi Centrum Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pannonia Maganorvosi Centrum Kft</name>
      <address>
        <city>Budapest</city>
        <zip>H-1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Melita Medical</name>
      <address>
        <city>Wroc≈Çaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-449</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Centrum Medyczne KERMED&quot;</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyczno - Lecznicze Barska sp. z o.o. Szpital</name>
      <address>
        <city>W≈Çoc≈Çawek</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi</name>
      <address>
        <city>Lodz</city>
        <state>L√≥dzkie</state>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point Profesor Kierkus</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Czestochowa</name>
      <address>
        <city>Czƒôstochowa</city>
        <zip>42-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oswiecimskie Centrum Badan Klinicznych Medicome Sp. z o.o.</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ETG Skierniewice</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Szczecinskie Centrum Medyczne</name>
      <address>
        <city>Szczecin</city>
        <zip>71-270</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>EuroMediCare Szpital Specjalistyczny z Przychodnia</name>
      <address>
        <city>Wroc≈Çaw</city>
        <zip>54-144</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ETG Zamosc</name>
      <address>
        <city>Zamo≈õƒá</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oblasna komunalna ustanova &quot;Chernivetska oblasna klinichna likarnia&quot;</name>
      <address>
        <city>Chernivtsi</city>
        <state>Chernivets'ka Oblast'</state>
        <zip>58001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;OK Clinic&quot;</name>
      <address>
        <city>Kyiv</city>
        <state>Ky√Øv</state>
        <zip>2091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KNP &quot;Odeska oblasna klinichna likarnia&quot; Odeskoi oblasnoi rady&quot;</name>
      <address>
        <city>Odesa</city>
        <state>Odes'ka Oblast'</state>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medychnyi Tsentr TOV &quot;KHELS KLINIK&quot; - viddil Gasrtroenterology, Hepatology and Endocrinology</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Komunalne nekomertsiine pidpryiemstvo &quot;Vinnytska miska klinichna likarnia #1&quot;</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KNP &quot;Zakarpatska oblasna klinichna likarnia imeni Andriia Novaka&quot; Zakarpatskoi oblasnoi rady</name>
      <address>
        <city>Uzhhorod</city>
        <state>Zakarpats'ka Oblast'</state>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KU &quot;6-A miska klinichna likarnia&quot;</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Zaporiz'ka Oblast'</state>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lansoprazole</keyword>
  <keyword>Los Angeles Grade</keyword>
  <keyword>Double-blind</keyword>
  <keyword>Active comparator-controlled</keyword>
  <keyword>Proton-pump inhibitor</keyword>
  <keyword>Dose selection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

